Lucy Black reviews Sisters in Yellow by Mieko Kawakami, published by Macmillan.

For decades, Rupert Murdoch built one of the world's most powerful media empires, shaping news coverage, political debate and elections across several countries. But what was it like to work inside that machine? Journalist turned academic Andrew Dodd has co-written Getting Murdoched.

Australia correspondent Chris Niesche looks at the controversy generated by One Nation's Pauline Hanson after she was interviewed on a podcast by far-right activist and convicted criminal Tommy Robinson.

A Kiwi startup is working to convert fragmented geographic data into an AI model that can better help with climate modelling for emergency and insurance forecasting.

Local blueberry growers are warning new planned import rules risk the introduction of new pests and diseases, which would damage production and could spread to other crops.

Sophie Roberts was a normal active teen until she started feeling dizzy and suffering seizures. Eating became hell. Her journey for answers is explored in a new RNZ podcast called All in Her Head.

Marc discusses Ryan Fox's historic Open Championship victory, and the FIFA World Cup which has come to an end.

In his new book, Great Tales of Aotearoa: Extraordinary Stories from New Zealand's Past, historian and author Tom Clarke brings together some of the most fascinating chapters from our past.

RNZ Economics correspondent Gyles Beckford discusses inflation which is at its highest level in more than two years - with the annual rate at 4.1 per cent.

Tensions have escalated as the government's fast-track planning process has begun overriding Auckland Council objections on several major infrastructure and housing developments, coinciding with a controversial $60 million state funding package to keep Fletcher Building's domestic cement plant operational. Thomas also discusses corporate expansions as Kiwi brand-tracking firm Tracksuit acquired Australian AI startup Hall to monitor digital brand presence, and AFT Pharmaceuticals secured crucial regulatory backing in the US and Japan for its novel iron injection treatment. Thomas Manch is a senior journalist at BusinessDesk.